Novo, GIC Back Singapore lab firm in US$200 million funding round yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.
Alongside the race for Covid-19 treatments and vaccines, the industry has maintained momentum
2020’s headlines have been dominated by coronavirus since the first reports of a mysterious virus causing pneumonia in Wuhan, China, in January. The pharmaceuticals sector’s response was huge. While the pharma landscape has been somewhat unusual this year, at least some business has carried on.
The need for effective and innovative ways to treat disease is something that even a global pandemic will not blunt
Of course, a lot of the focus on clinical trials this year has been Covid-19-related, but trials continue elsewhere, despite the challenges and delays the pandemic has caused. However, there has been disruption. According to Evaluate Pharma’s World preview 2020, outlook to 2026 report, ‘Hundreds of clinical trials have been mothballed and trial readouts delayed; smaller developers in particular are exposed here, as they rely on fresh data for financial injections and partnerin
December 09, 2020
When the Hong Kong Institute of Biotechnology was built in 1988, it was just a year after Singapore set up its Institute of Molecular and Cell Biology, the first research centre of its kind there.
Henry Wong
More than three decades after Hong Kong and Singapore separately embarked on growing biotechnology sectors at almost the same time, their outcomes have proven dramatically different.
Observers say Hong Kong’s efforts have sputtered and lagged behind Singapore’s strides in setting up a range of research institutions, attracting top talent and manufacturers, creating jobs and providing a launch pad for start-ups.
There is now a new urgency for Hong Kong to prove its prowess, given China’s five-year goal of self-sufficiency in technology.